These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 7546694)

  • 41. Ganciclovir intraocular implant.
    Morley MG; Duker JS; Reichel E
    Ophthalmology; 1996 Oct; 103(10):1517. PubMed ID: 8874416
    [No Abstract]   [Full Text] [Related]  

  • 42. [Treatment of CMV retinitis with intravitreal foscarnet].
    Cochereau I; Belayachi N; Diraison C; Matheron S; Bouyer I; Hoang-Xuan T; Saimot AG; Coulaud JP
    J Fr Ophtalmol; 1998 Dec; 21(10):723-6. PubMed ID: 10052044
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High-dose (5000-microg) intravitreal ganciclovir combined with highly active antiretroviral therapy for cytomegalovirus retinitis in HIV-infected patients in Venezuela.
    Arevalo JF; Garcia RA; Mendoza AJ
    Eur J Ophthalmol; 2005; 15(5):610-8. PubMed ID: 16167292
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cytomegalovirus retinitis and viral resistance: ganciclovir resistance. CMV Retinitis and Viral Resistance Study Group.
    Jabs DA; Enger C; Dunn JP; Forman M
    J Infect Dis; 1998 Mar; 177(3):770-3. PubMed ID: 9498461
    [TBL] [Abstract][Full Text] [Related]  

  • 45. New drugs for treating CMV. Valcyte, an oral compound, expands the treatment options for people with CMV retinitis.
    Eagan L
    Posit Living; 2001; 10(6):13. PubMed ID: 11702748
    [No Abstract]   [Full Text] [Related]  

  • 46. Influence of the response to induction therapy on the rate of progression of cytomegalovirus retinitis in AIDS patients on intravitreal maintenance therapy.
    López-Cortés LF; Pastor-Ramos T; Cordero E; Caballero-Granado FJ; Viciana P; Pachón J
    Eur J Clin Microbiol Infect Dis; 2001 Jun; 20(6):385-8. PubMed ID: 11476437
    [TBL] [Abstract][Full Text] [Related]  

  • 47. New issues in the management of cytomegalovirus retinitis in AIDS patients.
    Pau AK
    Am J Health Syst Pharm; 1998 Feb; 55(4):392-5. PubMed ID: 9504201
    [No Abstract]   [Full Text] [Related]  

  • 48. Therapeutic decisions: informed choices in a changing clinical environment.
    Holland GN
    Am J Ophthalmol; 1999 Mar; 127(3):327-8. PubMed ID: 10088744
    [No Abstract]   [Full Text] [Related]  

  • 49. Cost of sustained release treatment of CMV retinitis.
    Weitzner A
    Ophthalmology; 1993 Nov; 100(11):1602-3. PubMed ID: 8233378
    [No Abstract]   [Full Text] [Related]  

  • 50. CMV retinitis treatment.
    Thimons JJ
    Optom Vis Sci; 1995 May; 72(5):310-1. PubMed ID: 7667007
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Support for new foscarnet indication for AIDS-related CMV retinitis is mixed.
    AIDS Patient Care STDS; 1997 Oct; 11(5):377. PubMed ID: 11361828
    [No Abstract]   [Full Text] [Related]  

  • 52. Therapy for cytomegalovirus retinitis: still no silver lining.
    Young LH
    JAMA; 1996 Jan; 275(2):149-50. PubMed ID: 8531313
    [No Abstract]   [Full Text] [Related]  

  • 53. Endogenous bacterial endophthalmitis as a complication of intravenous therapy for cytomegalovirus retinopathy.
    Tufail A; Weisz JM; Holland GN
    Arch Ophthalmol; 1996 Jul; 114(7):879-80. PubMed ID: 8660177
    [No Abstract]   [Full Text] [Related]  

  • 54. CMV retinitis trial expanding.
    Vazquez E
    Posit Aware; 1998; 9(1):16. PubMed ID: 11364995
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Retinal toxicity of high dose intravitreal ganciclovir.
    Saran BR; Maguire AM
    Retina; 1994; 14(3):248-52. PubMed ID: 7973120
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment of cytomegalovirus retinitis with intravitreal injection of liposome encapsulated ganciclovir in a patient with AIDS.
    Akula SK; Ma PE; Peyman GA; Rahimy MH; Hyslop NE; Janney A; Ashton P
    Br J Ophthalmol; 1994 Sep; 78(9):677-80. PubMed ID: 7947546
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment of relapsed cytomegalovirus retinitis with the sustained-release ganciclovir implant.
    Hatton MP; Duker JS; Reichel E; Morley MG; Puliafito CA
    Retina; 1998; 18(1):50-5. PubMed ID: 9502281
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Intravitreal ganciclovir concentration after intravenous administration in AIDS patients with cytomegalovirus retinitis: implications for therapy.
    Kuppermann BD; Quiceno JI; Flores-Aguilar M; Connor JD; Capparelli EV; Sherwood CH; Freeman WR
    J Infect Dis; 1993 Dec; 168(6):1506-9. PubMed ID: 8245536
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. The Ganciclovir Implant Study Group.
    Musch DC; Martin DF; Gordon JF; Davis MD; Kuppermann BD
    N Engl J Med; 1997 Jul; 337(2):83-90. PubMed ID: 9211677
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Visual and anatomic outcomes associated with posterior segment complications after ganciclovir implant procedures in patients with AIDS and cytomegalovirus retinitis.
    Lim JI; Wolitz RA; Dowling AH; Bloom HR; Irvine AR; Schwartz DM
    Am J Ophthalmol; 1999 Mar; 127(3):288-93. PubMed ID: 10088738
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.